Track topics on Twitter Track topics that are important to you
Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality bladder conservative approach.
Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with histologically confirmed diagnosis of muscle-invasive urothelial carcinoma of the bladder.
The bladder preserving therapy include combined modality therapy with:
Investigational product (atezolizumab/Tecentriq ®):
- Route of administration: intravenous infusion.
- Duration of treatment: 16 weeks.
- Dosage: 1.200 mg intravenous every 3 weeks for a total of 6 doses. Atezolizumab is supplied as atezolizumab 1200 mg/20 mL vials (60 mg/mL) solution for intravenous infusion. After dilution, one mL of solution should contain approximately 4.4 mg of atezolizumab (1,200 mg/270 mL).
External Beam Radiation Therapy (EBRT): radiation
- Duration of treatment: 6 weeks
- Dosage: 60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2Gy/day
Adult patients (aged ≥18 years) with histologically confirmed diagnosis of muscle-invasive urothelial carcinoma of the bladder, in clinical stages T2-T4a who are not candidates for radical cystectomy by medical reasons, refusal or patient´s choice.
A total of 39 patients are estimated to be included in the study.
The primary objective of the study is to determine the efficacy of atezolizumab concurrent with radiotherapy in terms of pathological complete response defined as a response of grade 5 according to Miller and Payne criteria in patients with muscle-invasive bladder cancer treated with bladder preservation intent.
- To evaluate overall survival (OS).
- To evaluate disease specific survival (DSS).
- To evaluate disease free survival (DFS).
- To evaluate bladder intact disease-free survival (BIDFS).
- To calculate the number of patients with muscle invasive and non-muscle invasive local failure (LF).
- To determine the rate of distance metastases defined as the percentage of patients who develop metastases.
- To determine to the rate of patients with bladder preserved.
- To determine to the rate of immediate or late salvage cystectomy.
- The safety profile and tolerability of the combination of atezolizumab with concurrent radiotherapy.
- To determine the predictive role of the expression of PD-1 / PD-L1 and CD8 in terms of pCR, OS and DFS in bladder cancer patients treated with atezolizumab plus radiotherapy.
- The correlation between the levels of IFN-γ, interleukin 6 (IL-6), interleukin 18 (IL-18), or ITAC (also called CXCL11 or IP-9) and the efficacy parameters (pCR, OS and DFS) of the treatment with atezolizumab plus radiotherapy.
STUDY VISITS AND PROCEDURES:
The study includes the following visits:
- Screening: within the 28 days prior to starting the study treatment.
- Baseline visit: the first day of cycle 1
- Visits over the treatment period (16 weeks ± 7 days): from administration of the first dose of the study treatment to the administration of the last dose of atezolizumab or withdrawal from the treatment. Treatment will consist of the administration of atezolizumab at 1,200 mg intravenous every 3 weeks for 6 cycles
- Post-treatment follow-up: includes the biopsy and safety visit 1-2 months after the last dose of atezolizumab and a subsequent 5 years follow-up period after.
- End of study visit/ Early termination: In patients who end the study follow-up or prematurely withdraw from the study
Atezolizumab Injection [Tecentriq], External Beam Radiation Therapy (EBRT)
Althaia Xarxa Assintencial
Spanish Oncology Genito-Urinary Group
Published on BioPortfolio: 2019-12-10T01:21:00-0500
The main goals of deep hyperthermia combined with external beam radiation (EBRT) on bone metastases are the response on pain relief, duration of response and time to achieve complete pain ...
Two radiation therapy techniques are commonly used for the treatment of intermediate and high risk prostate cancer: brachytherapy and external beam radiation therapy (EBRT). However, both ...
The goal of this clinical research study is to learn if the combination of external beam radiation therapy (EBRT) and pembrolizumab can help control relapsed (has come back) and refractory...
The purpose of this study is to determine the feasibility of treating relapsed follicular lymphoma with a combination of Bexxar and EBRT. Patients will receive External Beam Radiation The...
The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as wel...
We sought to characterize temporal trends of radiation oncology resident-reported external beam radiation therapy (EBRT) case experience with respect to various disease sites, including trends in ster...
To investigate a Bayesian network (BN) based method to detect errors in external beam radiation therapy (EBRT) physician orders.
High-dose-rate brachytherapy (HDR-BT) is commonly combined with external beam radiation therapy (EBRT) for the treatment of localized prostate cancer. Escalating the HDR-BT dose as far as organ-at-ris...
Social contagion among physicians may affect the dissemination of innovative and high value cancer care. We applied social contagion theory to investigate the role of physician peer influence on the u...
External auditory canal cancer (EACC) is a rare malignant tumor. In the present study, we retrospectively evaluated the treatment results in patients with advanced EACC who were treated using external...
The use of an external beam of PROTONS as radiotherapy.
An optical source that emits photons in a coherent beam. Light Amplification by Stimulated Emission of Radiation (LASER) is brought about using devices that transform light of varying frequencies into a single intense, nearly nondivergent beam of monochromatic radiation. Lasers operate in the infrared, visible, ultraviolet, or X-ray regions of the spectrum.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
Organs which might be damaged during exposure to a toxin or to some form of therapy. It most frequently refers to healthy organs located in the radiation field during radiation therapy.
Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. military, purposes.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...